The partnership will help CBSET scale its integrated preclinical research & testing platform through significant capacity expansion and strategic add-on acquisitions

Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced it has completed a majority growth investment in Concord Biomedical Sciences and Emerging Technologies, Inc. (“CBSET” or the “Company”), a leading Boston-area provider of translational research and product development services for the medical device, pharmaceutical, diagnostic, and biomedical research industries.

CBSET offers a broad range of preclinical research and testing services as well as expert regulatory support for both FDA and global submissions. The Company performs GLP and non-GLP studies across a complete range of therapies with specialization in medical devices, targeted delivery of drugs, biologics, cell-based therapies, combination products and complex histopathology, histomorphometry, and image analysis. CBSET’s fully-integrated research platform is comprised of operating suites equipped with clinical grade imaging, advanced lab facilities, and highly experienced personnel that together enable customers to develop and execute complex research programs with customized endpoints to accelerate the advancement of medical devices and novel therapeutics.

“As the complexity of medical devices and advanced therapeutics continues to rise amid an increasingly stringent regulatory environment, the need for specialized preclinical research services has never been greater,” said Matt Altman, a Managing Partner at Arlington. “CBSET has established itself as a trusted partner for leading healthcare innovators across the globe. We look forward to supporting the development of their new state-of-the-art facility while also pursuing complementary acquisitions that will broaden the Company’s service offerings and further strengthen its position as a differentiated market leader.”

“As we evolve to meet the needs of an increasingly dynamic industry, we are excited to partner with Arlington in this next chapter,” said Peter Markham, CEO and Co-Founder of CBSET. “Their deep experience across the medical technology landscape makes them an ideal investment partner as we look to grow and expand our facilities and advance our novel capabilities.”

Dr. Elazer Edelman, Co-Founder of CBSET, added, “Our collaboration with Arlington comes at the perfect time as we respond to the evolving needs of the translational community. Together we are redefining approaches to the development and evaluation of innovations in therapeutics – assembling a world class cohort of experts and skilled staff in state-of-the-art, world class facilities for the greatest array of general and specialized tools, resources, and services.”

Gordon Auduong, a Managing Director at Arlington, added, “With deep expertise in high-growth areas such as interventional cardiology and structural heart, CBSET is a critical partner to customers in the advancement of innovative and essential treatments and technologies. We look forward to leveraging our own experience in the healthcare manufacturing sector to help the Company accelerate this life-saving work.”

Arlington has an extensive track record of building leading companies in highly regulated industries that are critical to healthcare infrastructure, government systems, and national security. Within healthcare, Arlington focuses on working with businesses that save lives, improve the delivery of products and services, and reduce costs for patients and providers. Recent investments include TEAM Technologies, Riverpoint Medical, Millstone Medical Outsourcing, and Grand River Aseptic Manufacturing.

Fairmount Partners served as financial advisor and DLA Piper LLP served as legal advisor to Arlington Capital Partners.

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private investment firm specializing in government-regulated industries. The firm partners with founders and management teams to build strategically important businesses in the healthcare, government services and technology, and aerospace and defense sectors. Since its inception in 1999, Arlington has invested in over 180 companies and has raised ~$14 billion in committed capital. For more information, visit Arlington’s website at www.arlingtoncap.com and follow Arlington on LinkedIn.

About CBSET

Founded in 2006, CBSET is a leading Boston-area provider of translational research and product development services for the medical device, pharmaceutical, diagnostic, and biomedical research industries. The Company offers a broad range of research services, including GLP and non-GLP studies, across medical device testing, drug and cell-based therapies, histopathology and morphometry, and regulatory support. With deep expertise in interventional cardiology, structural heart, and cardiovascular markets, CBSET partners with leading healthcare OEMs globally to accelerate device development and novel therapeutics. For more information, visit cbset.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251001678891/en/